Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ZM-H1505R in Healthy Subjects and Chronic Hepatitis B Patients
NCT05470829Phase 1Completed
- Sponsor
- Zhimeng Biopharma
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Canocapavir in Chronic Hepatitis B (CHB) (4 arms), sponsored by Zhimeng Biopharma. Primary endpoints: Safety and Tolerability Evaluation at 56 days, Pharmacokinetics Indicators at 42 days and 1 more. Started May 2021; status: completed.
02
Drugs
Canocapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05470829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470829.